179 related articles for article (PubMed ID: 23815869)
1. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.
Ekshyyan O; Moore-Medlin TN; Raley MC; Sonavane K; Rong X; Brodt MA; Abreo F; Alexander JS; Nathan CA
BMC Cancer; 2013 Jul; 13():320. PubMed ID: 23815869
[TBL] [Abstract][Full Text] [Related]
2. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer.
Patel V; Marsh CA; Dorsam RT; Mikelis CM; Masedunskas A; Amornphimoltham P; Nathan CA; Singh B; Weigert R; Molinolo AA; Gutkind JS
Cancer Res; 2011 Nov; 71(22):7103-12. PubMed ID: 21975930
[TBL] [Abstract][Full Text] [Related]
3. 3-O-Acetyloleanolic acid inhibits VEGF-A-induced lymphangiogenesis and lymph node metastasis in an oral cancer sentinel lymph node animal model.
Hwang-Bo J; Bae MG; Park JH; Chung IS
BMC Cancer; 2018 Jul; 18(1):714. PubMed ID: 29976150
[TBL] [Abstract][Full Text] [Related]
4. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
[TBL] [Abstract][Full Text] [Related]
5. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis.
Kobayashi S; Kishimoto T; Kamata S; Otsuka M; Miyazaki M; Ishikura H
Cancer Sci; 2007 May; 98(5):726-33. PubMed ID: 17425689
[TBL] [Abstract][Full Text] [Related]
6. Targeting VEGFR-3/-2 signaling pathways with AD0157: a potential strategy against tumor-associated lymphangiogenesis and lymphatic metastases.
García-Caballero M; Paupert J; Blacher S; Van de Velde M; Quesada AR; Medina MA; Noël A
J Hematol Oncol; 2017 Jun; 10(1):122. PubMed ID: 28629427
[TBL] [Abstract][Full Text] [Related]
7. Genetic Identification of SEMA3F as an Antilymphangiogenic Metastasis Suppressor Gene in Head and Neck Squamous Carcinoma.
Doçi CL; Mikelis CM; Lionakis MS; Molinolo AA; Gutkind JS
Cancer Res; 2015 Jul; 75(14):2937-48. PubMed ID: 25952650
[TBL] [Abstract][Full Text] [Related]
8. Inducible nitric oxide synthase activity correlates with lymphangiogenesis and vascular endothelial growth factor-C expression in head and neck squamous cell carcinoma.
Franchi A; Massi D; Santucci M; Masini E; Rossi Degl'Innocenti D; Magnelli L; Fanti E; Naldini A; Ardinghi C; Carraro F; Gallo O
J Pathol; 2006 Feb; 208(3):439-45. PubMed ID: 16278821
[TBL] [Abstract][Full Text] [Related]
9. Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models.
Sobral LM; Sousa LO; Coletta RD; Cabral H; Greene LJ; Tajara EH; Gutkind JS; Curti C; Leopoldino AM
Mol Cancer; 2014 Feb; 13():32. PubMed ID: 24555657
[TBL] [Abstract][Full Text] [Related]
10. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
11. PI3K/mTOR inhibitor PF-04691502 antitumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer.
Herzog A; Bian Y; Vander Broek R; Hall B; Coupar J; Cheng H; Sowers AL; Cook JD; Mitchell JB; Chen Z; Kulkarni AB; Van Waes C
Clin Cancer Res; 2013 Jul; 19(14):3808-19. PubMed ID: 23640975
[TBL] [Abstract][Full Text] [Related]
12. Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma.
Tsujikawa T; Yaguchi T; Ohmura G; Ohta S; Kobayashi A; Kawamura N; Fujita T; Nakano H; Shimada T; Takahashi T; Nakao R; Yanagisawa A; Hisa Y; Kawakami Y
Int J Cancer; 2013 Jun; 132(12):2755-66. PubMed ID: 23180648
[TBL] [Abstract][Full Text] [Related]
13. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
14. A retroinhibition approach reveals a tumor cell-autonomous response to rapamycin in head and neck cancer.
Amornphimoltham P; Patel V; Leelahavanichkul K; Abraham RT; Gutkind JS
Cancer Res; 2008 Feb; 68(4):1144-53. PubMed ID: 18281490
[TBL] [Abstract][Full Text] [Related]
15. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling.
He Y; Kozaki K; Karpanen T; Koshikawa K; Yla-Herttuala S; Takahashi T; Alitalo K
J Natl Cancer Inst; 2002 Jun; 94(11):819-25. PubMed ID: 12048269
[TBL] [Abstract][Full Text] [Related]
16. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
17. Liposomal honokiol inhibits VEGF-D-induced lymphangiogenesis and metastasis in xenograft tumor model.
Wen J; Fu AF; Chen LJ; Xie XJ; Yang GL; Chen XC; Wang YS; Li J; Chen P; Tang MH; Shao XM; Lu Y; Zhao X; Wei YQ
Int J Cancer; 2009 Jun; 124(11):2709-18. PubMed ID: 19219913
[TBL] [Abstract][Full Text] [Related]
18. Head and neck squamous cell carcinoma lymphatic spread and survival: Relevance of vascular endothelial growth factor family for tumor evaluation.
de Sousa EA; Lourenço SV; de Moraes FP; Vartanian JG; Gonçalves-Filho J; Kowalski LP; Soares FA; Coutinho-Camillo CM
Head Neck; 2015 Oct; 37(10):1410-6. PubMed ID: 24824527
[TBL] [Abstract][Full Text] [Related]
19. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.
Sano D; Matsumoto F; Valdecanas DR; Zhao M; Molkentine DP; Takahashi Y; Hanna EY; Papadimitrakopoulou V; Heymach J; Milas L; Myers JN
Clin Cancer Res; 2011 Apr; 17(7):1815-27. PubMed ID: 21350000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]